MMMinoo Mohraz

Minoo Mohraz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minoo Mohraz has a total of 224 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Phase III, Randomized, Double-Blind, Active-Controlled Non-Inferiority Trial Evaluating the Immunogenicity and Safety of Gardisun, a Quadrivalent Human Papillomavirus Vaccine, Compared with Gardasil® in Healthy Volunteers Aged 15–35 Years

    by Erfan Pakatchian, Minoo Mohraz, Mohammad Taghavian, Babak Javadimehr, Hajar Mohammadi Barzelighi, Majid Teymoori-Rad, Mehrdad Ghodsi, Zahra Naderi Saffar

    Background/Objectives: Human papillomavirus (HPV) infection is the leading cause of cervical cancer and is associated with several anogenital and oropharyngeal malignancies. Although licensed HPV vaccines are highly effective, access remains limited in many low- and middle-income countries due to cost, supply shortages, and implementation barriers. In this study, we evaluated the immunogenicity and safety of Gardisun, a newly developed quadrivalent prophylactic HPV vaccine, compared with GardasilÂŽ. Methods: This Phase III randomized, double-blind, active-controlled, parallel-group non-inferiority trial enrolled 450 healthy participants stratified by sex and randomized (1:1) to receive three 0.5 mL intramuscular doses of Gardisun or GardasilÂŽ on Days 0, 60, and 180. Participants were followed through to Day 210. The primary endpoint was the geometric mean titer (GMT) of antibodies against HPV types 6, 11, 16, and 18 one month after the administration of the third dose. Non-inferiority was defined as the lower bound of the 95% confidence interval (CI) for the GMT ratio exceeding 0.67. Safety was assessed through adverse event monitoring. Results: Of the 450 randomized participants, 422 completed the Month 7 visit and 429 received all three doses. Both vaccines induced antibody responses and seroconversion rates for all HPV types. The primary analysis met the non-inferiority criterion for HPV-6, while prespecified sensitivity analyses supported the existence of non-inferiority across all evaluated HPV types. Most adverse events were mild and transient, with no vaccine-related serious adverse events reported. Conclusions: Gardisun demonstrated robust immunogenicity and a safety profile comparable to that of GardasilÂŽ, supporting its potential as an accessible alternative quadrivalent HPV vaccine for broader vaccination programs in resource-limited settings.

  • Open Access

    The prevalence of HTLV-1 co-infection among people living with HIV in a tertiary care hospital in Tehran: a cross-sectional study

    by Elnaz Shahmohamadi, Ali Akbari Sari, Esmaeil Mehraeen, Malihe Hassan Nezhad, Amirali Karimi, Pegah Mirzapour, Peyman Mirghaderi, Zahra Pashaei, Hossein Keivani, Minoo Mohraz, et al.

    Introduction: Human immunodeficiency virus (HIV) and human T cell leukemia/lymphoma virus type 1 (HTLV-1) share similar routes of transmission and both target T cells. HTLV-1 may negatively affect the course of disease in people living with HIV, but previous evidence is conflicting....


  • Prevalence, Demographic Correlates, and Medical Correlates of Cognitive Impairment Among Iranian People Living With HIV: A Cross-sectional Survey Study

    by Maede S. Etesami, Deborah L. Jones, Vahid Sadeghi-Firoozabadi, Ladan Abbasian, Morteza Ghayomzadeh, Minoo Mohraz, David E. PhD Vance, Lucette A. Cysique, Mojtaba Habibi Asgarabad

    While taking antiretroviral therapy, 30%–60% of people living with HIV (PLWH) experience neurocognitive impairment (NCI). To determine NCI prevalence among Iranian PLWH, by the computerized Vienna Test System, 63 adults living without HIV and 63 Iranian PLWH aged 18–50 years (M = 35.3, SD = 7.9) were assessed for cognitive function. NCI was determined by receiver operating characteristic curve cutoff points based on the adults living without HIV. Associations between demographics, HIV serostatus markers, and mean T-scores were investigated. Performance differences were tested by including significant covariates in an analysis of covariance. NCI prevalence rates were 57.14% in PLWH and 19.05% in adults living without HIV. Global neurocognitive performance and all cognitive domains were significantly different between the groups, except for visual memory and selective attention. In Iran, NCI prevalence parallels that reported in PLWH worldwide. There should be a strategy to screen Iranian PLWH for NCI.


  • Sociodemographic Characteristics, HIV-Related Risk Behaviors and HIV Prevalence of Vulnerable Men in Tehran, Iran

    by Minoo Mohraz, SeyedAhmad SeyedAlinaghi, Ali Asadollahi-Amin, Rahele Golrokhi, Effat Merghati Khoei, Habib Yousefi, Fatemeh Jafari, Omid Dadras

    Background: Sexual minorities, such as men who have sex with men (MSM), are disproportionately impacted by HIV/AIDS compared to heterosexual men. The increased prevalence of HIV/AIDs among this group of individuals is associated with increased participation in HIV-related risk behavior, such as multiple sexual partnerships and injection drug use. However, very little is known about the prevalence of HIV and the risk behaviors related to HIV infection among MSM in Iran. This absence of data is due to the increased discrimination and stigmatization MSM, and other vulnerable populations face in Iran. This study was conducted to identify HIV-related risks, HIV prevalence and sociodemographic characteristics of the MSM population in Iran. Methods: A cross-sectional study was conducted among MSM attending the Sexual Health Clinic at Imam Khomeini Hospital in 2018. A sexual health screening questionnaire was used to aid in identifying HIV-related risk behaviors. HIV status was determined using an HIV rapid test and confirmed by an ELISA. Results: One hundred MSM enrolled in this study, out of which 41% were 18-25 years old. The majorities were single; almost one-third had a diploma degree. Only a fifth were employed, and about a quarter (25%) reported substance abuse. Among eighty-three people (83%) reported having sex during the past three months, and only 27 (27.3%) of participants always used condoms for sex. Among 80 participants tested for HIV, two positive results were detected (2.5%). Conclusion: Data collected through a sexual health questionnaire indicated that the prevalence of HIV is increased among MSM in Iran. This finding sheds light on the urgent need for the implementation of social programs providing counseling and healthcare to vulnerable populations in Iran.


  • Expression of mir-221, mir-29a, mir-155 and mir-146a in Peripheral Blood Mononuclear Cell (PBMC) in HIV-1 Infected Patients

    by Arsalan Narouei, Negin Hosseini Rouzbahani, Maryam Ghanbari, Leila Taj, Minoo Mohraz, Mohammad Gholami, Kazem Baesi

    Background and Aim: patients infected by HIV-1, some cellular biomarkers such as microRNAs have an important function in the suppression or progression of the disease. The aim of the current study is to evaluate the expression of mir-221, mir-29a, mir-155, and mir-146a in HIV-1 infected patients. Methods: The miRNAs of 60 HIV-1 infected patients (sample group) and 20 healthy controls (normal group) were extracted from their peripheral mononuclear cells. We used TaqMan-based Real-- time PCR for evaluation of expression mir-155, mir-221, mir-29a and mir-146a by the comparative method. To evaluate differences among the data, one-way ANOVA was used. The expression of mir-155 and mir-146a in HIV-1 patients (sample group) was down-regulated in comparison with healthy controls (normal group) with a confidence value (***p<0.001). In addition, in the sample group, the expression of mir-221 was downregulated compared to the normal group (***p<.001). Results: There was no significant difference in expression mi-29a in the sample and control group. In the sample group, mir-221 had a low expression, and mir-29a had a high expression, respectively. According to the results of the current study and comparative studies, it seems that the microRNA has an important role in the progression or suppression of HIV-1 infection. Conclusion: However, the data showed that besides other cellular and viral factor, these miRNAs could be used as a biomarker. However, the miRNAs field experts are in general agreement that more investigation is needed to use miRNAs as a biomarker in HIV.


  • Single‐pill sofosbuvir and daclatasvir for treating hepatis C in patients co‐infected with human immunodeficiency virus

    by Seyed Ali Dehghan Manshadi, Shahin Merat, Minoo Mohraz, Mehrnaz Rasoolinejad, Shanaz Sali, Masoud Mardani, Payam Tabarsi, Mohammad‐Hossein Somi, Roya Sedghi, Katayoun Tayeri, et al.

    Background The current recommendation for treating hepatitis C virus (HCV) in HIV patients includes the combination of sofosbuvir (SOF) and daclatasvir (DCV). DCV should be used at different doses to compensate for interactions with antiretroviral therapy (ART). Up to three pills a day might be required which will significantly add to the pill burden of these patients. In this study, we have used a single‐tablet approach to treating HCV‐HIV coinfection. Methods Patients coinfected with HIV and HCV were prospectively enrolled from 10 centers throughout the country. Patients received a single once‐daily fixed dose combination (FDC) pill containing 400 mg SOF and 30, 60 or 90 mg DCV depending on the type of ART they were receiving for 12 or 24 weeks. (ClinicalTrials.gov ID: NCT03369327). Results Two hundred thirty‐three patients were enrolled from 10 centers. Twenty‐three patients were lost to follow‐up and two patients died from causes unrelated to treatment. Two hundred eight patients completed the treatment course of which 201 achieved SVR (96.6%). Conclusion Single‐tablet combination of DCV and SOF is an effective and safe treatment for patients coinfected with HIV and HCV. The combination works well in patients on ART in which dose adjustment is required. Patients with cirrhosis, previous treatment failure and various genotypes respond identically. The expenses of genotyping can be saved.


  • HIV in Iran: onset, responses, and future directions

    by SeyedAhmad SeyedAlinaghi, Leila Taj, Elham Mazaheri-Tehrani, Sara Ahsani-Nasab, Negin Abedinzadeh, Willi McFarland, Minoo Mohraz, Ali Mirzazadeh

    Iran, a country in the Middle East and North Africa (MENA) region, has been actively involved in the fight against HIV/AIDS over the past three decades. The unique features of the HIV epidemic in Iran are reflected by the modes of transmission and its recent changes to improve management and prevention programs. In this review, we recount the initial onset and subsequent spread of HIV infection in Iran, beginning with the first case diagnosed to the ongoing responses and most recent achievements in controlling this epidemic. Although in the MENA region, Iran is one of the pioneers in implementing pertinent policies including harm reduction services to decrease HIV incidence, drug injection still continues to be the major risk of infection. In line with other nations, the programs in Iran aim at the UNAIDS 90-90-90 targets (UNAIDS 90-90-90 global targets to end the AIDS epidemic by 2020: by 2020, 90% of all people living with HIV will know their HIV status; 90% of all people with diagnosed HIV infection will receive sustained antiretroviral therapy; and 90% of all people receiving antiretroviral therapy will have viral suppression) and to eliminate mother-to-child HIV transmission. In this article, we discuss the strengths and shortcomings of the current HIV programs and offer suggestions to provide a better perspective to track and respond to the HIV epidemic. More generally, our account of the national religious and cultural circumstances as well as obstacles to the approaches chosen can provide insights for decision-makers in other countries and institutions with comparable settings and infrastructures.


  • Qualitative analysis of attitudes, behaviors, and demands of vulnerable men in Tehran, Iran

    by Minoo Mohraz, SeyedAhmad SeyedAlinaghi, Ali Asadollahi-Amin, Rahele Golrokhi, Effat Merghati Khoei, Habib Yousefi, Salar Pashangzadeh, Omid Dadras

    Introduction: Men who have sex with men (MSM) are a vulnerable group, and their psychological, physical, and social well-being could be affected by various factors. They are also at higher risk of HIV and other sexually transmitted infections (STIs). This study was conducted to identify socio-demo-graphic characteristics and HIV-related risk behaviors among MSM in Iran. Material and methods: A qualitative study was conducted among MSM attending a sexual health clinic in a referral hospital, in Tehran in 2018. Data was collected through four focus group discussions. Con-tent analysis approach was used in data analysis. Results: One hundred MSM were enrolled in this study. Majority of them were 18-25 years old. Partic-ipants had numerous comments about their sexual identity and orientation; some were confused about it and mentioned stigma, discrimination, and lack of social and legal support as the most important contributing factors. Social media and parties were the most common places to find a partner. Moreover, majority had a negative attitude toward emotional attachment and marriage in sexual minorities; this was attributed to partner's infidelity, low commitment, and lack of family support by some participants. Conclusions: MSM is a vulnerable to psychosocial problems group due to low sexual knowledge and lack of community and legal supports. Data also indicated high probability of HIV transmission among this group because of risky sexual behaviors.


  • Combination of resistance and aerobic exercise for six months improves bone mass and physical function in HIV infected individuals: A randomized controlled trial

    by Morteza Ghayomzadeh, Conrad P. Earnest, Daniel Hackett, SeyedAhmad SeyedAlinaghi, James Wilfred Navalta, Mohammad Gholami, Negin Hosseini Rouzbahani, Minoo Mohraz, Fabrício Azevedo Voltarelli

    To evaluate the effect of combined resistance and aerobic training (RT+AT) on regional bone mineral density (BMD) and physical performance in people living with HIV (PLWH). Forty PLWH (20 men and 20 women) were randomized into RT+AT group (n = 20; age = 38.3 ± 4.9) or non‐exercise control group (n = 20; age = 37.9 ± 5.1). The RT+AT group was required to perform a nonlinear periodized resistance training program targeting large muscle groups followed by 20 min aerobic exercise at 65‐80% of maximal heart rate. Participants in RT+AT performed three supervised sessions per week for 6‐months, whereas participants in the control group were instructed to continue with their current lifestyle habits. The primary outcome was bone mineral density (lumbar spine (L2‐L4), femoral neck, and distal 1/3 radius). Secondary outcomes included physical function, anthropometry, inflammatory markers, and growth factors. The RT+AT group demonstrated a significant increase in BMD at follow‐up for the Lumbar spine (L2‐L4), femoral neck, and 1/3 radius (all, P < .05), and There were no gender differences in the training response between men and women for any of the BMD regions. Similar findings were also observed for lean body mass, IGF1and Adiponectin (P < .001). We observed a decrease in percent body fat, fat mass, IL‐6, TNF‐α, and myostatin in the RT+AT group (P < .001). Finally, there was a significant increase in handgrip strength and gait speed for both women and men in the RT+AT group (P < .001). A combination of resistance and aerobic training appears to be a feasible and effective means for counteracting bone loss and improving various inflammatory markers, physical function, and growth hormones in PLWH.


  • HIV-1 drug resistance mutations detection and HIV-1 subtype G report by using next-generation sequencing platform

    by Mohammad Gholami, NeginHosseini Rouzbahani, SiamakMirab Samiee, Katayoun Tayeri, Khodayar Ghorban, Alireza Dolatyar Dehkharghani, Ali Akbar Gholami, Farzaneh Moshiri, Arash Sattari, Maryam Dadmanesh, et al.